TEE
PTGX icon

Tibra Equities Europe’s Protagonist Therapeutics PTGX Stock Holding History

Tibra Equities Europe’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-32,647
Closed -$410K – 398
2019
Q1 		$410K Buy
+32,647
New +$288K 0.04% 285

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Tibra Equities Europe's PTGX Position: Q2 2019 in Review

Tibra Equities Europe sold out of Protagonist Therapeutics (PTGX) in Q2 2019, closing a stake of 32,647 shares — an estimated $410K sold.

Tibra Equities Europe first reported a position in PTGX in Q1 2019 and held it in 1 quarter. The position peaked at $410K in Q1 2019. 66 funds tracked by Wall St. Rank hold PTGX as of Q2 2019.

  • Tibra Equities Europe reported no remaining Protagonist Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 32,647 Protagonist Therapeutics shares in Q2 2019, an estimated $410K.
  • Tibra Equities Europe first reported a position in Protagonist Therapeutics in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Protagonist Therapeutics position peaked at $410K in Q1 2019.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.